A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF

被引：8

作者：

Talpaz, Moshe ^{[1
]}

Jamieson, Catriona ^{[2
]}

Gabrail, Nashat Y. ^{[3
]}

Lebedinsky, Claudia ^{[4
]}

Gao, Guozhi ^{[4
]}

Liu, Feng ^{[5
]}

Tefferi, Ayalew ^{[6
]}

Pardanani, Animesh ^{[6
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[3] Gabrail Canc Ctr, Canton, OH USA

[4] Sanofi, Oncol Res & Dev, Cambridge, MA USA

[5] Sanofi, Translat & Expt Med, Cambridge, MA USA

[6] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

来源：

关键词：

D O I：

10.1182/blood.V120.21.2837.2837

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2837

引用

页数：2